GlassScriptPhysician profile
Janine Durant
NPI 1740863489
$2,721.77
in general payments reported to CMS, 2019-2025
30 companies · $806 in 2025
The $806 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.89 · 2022: $303 · 2023: $705 · 2024: $848 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.74 |
| Education | $348.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $740.39 | 2023-2025 | Veozah, Myrbetriq, Xtandi |
| Urogen Pharma, INC. | $285.97 | 2023-2025 | |
| Medtronic, INC. | $218.97 | 2021-2024 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $209.24 | 2021-2025 | |
| Tolmar, INC. | $153.82 | 2024-2025 | Eligard, Jatenzo |
| Antares Pharma, INC. | $145.99 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Sumitomo Pharma America, INC. | $118.04 | 2023-2025 | Gemtesa |
| 180 Medical, INC. | $80.20 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $72.94 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Urovant Sciences INC | $62.99 | 2022 | |
| Abbvie INC. | $58.99 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $56.90 | 2025 | Provenge |
| Boston Scientific Corporation | $54.73 | 2025 | General - Female Sui |
| Endo Pharmaceuticals INC. | $54.22 | 2022-2023 | Xiaflex |
| Ferring Pharmaceuticals INC. | $52.49 | 2025 | Adstiladrin |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $41.73 | 2024-2025 | Posluma |
| Endo USA, INC. | $31.16 | 2025 | Aveed, Xiaflex |
| Progenics Pharmaceuticals, INC. | $29.79 | 2023-2024 | Pylarify |
| Mayne Pharma Commercial LLC | $27.34 | 2023 | |
| Procept Biorobotics Corporation | $25.21 | 2023 | Aquabeam Robotic System |
| Teleflex LLC | $24.61 | 2025 | Barrigel |
| Sun Pharmaceutical Industries INC. | $23.60 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.85 | 2025 | Givlaari |
| Novartis Pharmaceuticals Corporation | $22.77 | 2024 | |
| Janssen Biotech, INC. | $19.60 | 2025 | Erleada |
| Astrazeneca Pharmaceuticals LP | $19.02 | 2022 | |
| Verity Pharmaceuticals INC. | $18.14 | 2023 | Trelstar |
| Halozyme INC | $17.05 | 2023 | |
| Palette Life Sciences, INC. | $16.59 | 2022 | |
| Olympus America INC. | $16.43 | 2023 | Itind System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janine Durant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.